Share-based Payment Arrangement, Expense of ANAPTYSBIO, INC from 31 Mar 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ANAPTYSBIO, INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2021 to 30 Sep 2025.
  • ANAPTYSBIO, INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9,157,000, a 12% increase year-over-year.
  • ANAPTYSBIO, INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $35,750,000, a 5.2% increase year-over-year.
  • ANAPTYSBIO, INC annual Share-based Payment Arrangement, Expense for 2024 was $34,048,000, a 2.5% increase from 2023.
  • ANAPTYSBIO, INC annual Share-based Payment Arrangement, Expense for 2023 was $33,205,000, a 21% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ANAPTYSBIO, INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $35,750,000 $9,157,000 +$968,000 +12% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $34,782,000 $9,239,000 +$1,695,000 +22% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $33,087,000 $9,170,000 -$961,000 -9.5% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q1
Q4 2024 $34,048,000 $8,184,000 +$73,000 +0.9% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $33,975,000 $8,189,000 +$382,000 +4.9% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $33,593,000 $7,544,000 -$883,000 -10% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $34,476,000 $10,131,000 +$1,271,000 +14% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q1
Q4 2023 $33,205,000 $8,111,000 +$1,426,000 +21% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $31,779,000 $7,807,000 +$1,536,000 +24% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $30,243,000 $8,427,000 +$1,769,000 +27% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $28,474,000 $8,860,000 +$1,118,000 +14% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $27,356,000 $6,685,000 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $6,271,000 +$1,907,000 +44% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $6,658,000 +$2,968,000 +80% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $7,742,000 +$4,427,000 +134% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 $4,364,000 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $3,690,000 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $3,315,000 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1

ANAPTYSBIO, INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $34,048,000 +$843,000 +2.5% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $33,205,000 +$5,849,000 +21% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $27,356,000 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.